Compare Gilead Sciences, Inc. (GILD) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Newmont Corporation — how do they compare? Gilead Sciences, Inc. trades at $133.5 (market cap $163.51B), while Newmont Corporation trades at $91.41 (market cap $101.64B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | NEM | |
|---|---|---|
Market Cap | $163.51B | $101.64B |
Sector | Health | Basic Materials |
52-Week High | $155.80 | $131.95 |
52-Week Low | $108.22 | $57.99 |
Enterprise Value | $178.05B | $98.39B |
Dividend Yield | 2.49% | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Newmont Corporation (NEM) trades at $91.73, down 3.19% over the past day amid gold price volatility. The stock shows strong fundamentals with a P/E of 12.35, net income margin of 33.87%, and three consecutive quarterly earnings beats. Technical indicators are neutral with support at $91 and resistance at $96. Recent news highlights mixed sentiment due to gold's decline but positive long-term outlook from analysts.
NEM presents a compelling value with robust cash flow growth and a bullish analyst consensus (75.68% buy ratings) targeting $140.11. Key risks include higher unit costs pressuring 2026 margins and gold price sensitivity. The stock's current dip may offer entry opportunity given strong fundamentals and institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
